MedTrace Logo

A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

NCT07589244 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-05-15

No results posted yet for this study

Summary

This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).

Conditions

Interventions

DRUG

VRT106

VRT106,Intravenous infusion

DRUG

VRT106 in combination with camrelizumab and apatinib

VRT106: Intravenous infusion Camrelizumab: Intravenous infusion Apatinib: Oral administration

DRUG

Investigator's Choice of Standard of Care

At the investigator's discretion

Sponsors & Collaborators

  • Guangzhou Virotech Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Liang Peng · Third Affiliated Hospital, Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-13
Primary Completion
2028-12-31
Completion
2029-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07589244 on ClinicalTrials.gov